Moreover, the 36-month beta value for CLDI is 0.60. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CLDI is 6.14M and currently, short sellers hold a 1.81% of that float. On October 28, 2024, CLDI’s average trading volume was 157.72K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CLDI) stock’s latest price update
Calidi Biotherapeutics Inc (AMEX: CLDI)’s stock price has gone rise by 29.76 in comparison to its previous close of 0.84, however, the company has experienced a -10.66% decrease in its stock price over the last five trading days. accesswire.com reported 2024-10-25 that ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET).
CLDI’s Market Performance
CLDI’s stock has fallen by -10.66% in the past week, with a monthly drop of -9.92% and a quarterly drop of -27.81%. The volatility ratio for the week is 29.71% while the volatility levels for the last 30 days are 13.46% for Calidi Biotherapeutics Inc The simple moving average for the last 20 days is 1.90% for CLDI’s stock, with a simple moving average of -68.84% for the last 200 days.
Analysts’ Opinion of CLDI
Many brokerage firms have already submitted their reports for CLDI stocks, with H.C. Wainwright repeating the rating for CLDI by listing it as a “Buy.” The predicted price for CLDI in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on November 22, 2023 of the previous year 2023.
Robert W. Baird, on the other hand, stated in their research note that they expect to see CLDI reach a price target of $9. The rating they have provided for CLDI stocks is “Outperform” according to the report published on October 09th, 2023.
CLDI Trading at -5.44% from the 50-Day Moving Average
After a stumble in the market that brought CLDI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.28% of loss for the given period.
Volatility was left at 13.46%, however, over the last 30 days, the volatility rate increased by 29.71%, as shares sank -9.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.57% lower at present.
During the last 5 trading sessions, CLDI fell by -10.66%, which changed the moving average for the period of 200-days by -92.21% in comparison to the 20-day moving average, which settled at $1.0697. In addition, Calidi Biotherapeutics Inc saw -92.78% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CLDI
The total capital return value is set at 4.47. Equity return is now at value -238.50, with -92.17 for asset returns.
Based on Calidi Biotherapeutics Inc (CLDI), the company’s capital structure generated -1.08 points at debt to capital in total, while cash flow to debt ratio is standing at -5.09. The debt to equity ratio resting at -0.52. The interest coverage ratio of the stock is -27.58.
Currently, EBITDA for the company is -27.74 million with net debt to EBITDA at -0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.12.
Conclusion
To wrap up, the performance of Calidi Biotherapeutics Inc (CLDI) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
